Drugs / Eschscholtzia Californica
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT02187588 | Feb 1998 → May 1999 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02183233 | Jan → Jun 1998 | sleep disorder, initiating and maintaining sleep | Boehringer Ingelheim | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Eschscholtzia Californica | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02183233 ↗ |
| Route | Oral | “500 mg and 1000 mg of Eschscholtzia californica per os” NCT02187588 ↗ |